MedTrace Logo

Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy

NCT02153151 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2025-05-02

No results posted yet for this study

Summary

This pilot research trial studies the response in blood cells to AMP-514, a drug shown to increase immune response (capacity to fight against infections and cancer) against cancer in patients with solid tumors undergoing radiotherapy. Measuring changes in biomarkers may help doctors decide if AMP-514 should be combined with radiotherapy and when is the best time to combine the drug with radiation.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

OTHER

Cytology specimen

Correlative studies

OTHER

Laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Voichita Bar-Ad, MD · Thomas Jefferson University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-11
Primary Completion
2016-02-23
Completion
2016-07-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02153151 on ClinicalTrials.gov